Andere talen Ocular Therapeutix, Inc.

Aandelen

OCUL

US67576A1007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,745 ^USD	+12,98%		-9,10%	+6,39%

18/04	Ocular Therapeutix, Inc. Kondigt positieve topline Fase 1 gegevens aan voor AXPAXLI? in diabetische retinopathie	CI
15/04	Ocular Therapeutix, Inc. Kondigt wijzigingen in de leiding aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19/04
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	18/04
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	18/04
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	18/04
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy	18/04
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18/04
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	16/04
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders	16/04
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	15/04
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	15/04
Ocular Therapeutix, Inc. Announces Executive Changes	15/04
Ocular Therapeutix, Inc. Announces CEO Changes	15/04
Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4) to Senior Vice President of Global Head of Biometrics	10/04
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics	09/04
Ocular Therapeutix Announces Positive Phase 2 PAXTRAVA Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	08/04
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06/04
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06/04
Ocular Therapeutix to Present Data at the 2024 ASCRS Annual Meeting	27/03
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)	26/03
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours	25/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ocular Therapeutix, Inc.

Aandelen

OCUL

US67576A1007

Andere talen

Filters